Pages that link to "Q35787456"

The following pages link to Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics (Q35787456):

Displayed 50 items.

• Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients (Q21195017) ‎ (← links)
• Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India (Q21261889) ‎ (← links)
• Use of antibiotics in the treatment of Crohn's disease (Q22241216) ‎ (← links)
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis (Q22251072) ‎ (← links)
• Invasive Escherichia coli are a feature of Crohn's disease (Q22251106) ‎ (← links)
• Innate immunity in inflammatory bowel disease: a disease hypothesis (Q22252859) ‎ (← links)
• Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohnʼs Disease (Q22252899) ‎ (← links)
• Probiotics for maintenance of remission in ulcerative colitis (Q24234400) ‎ (← links)
• Probiotics for maintenance of remission in ulcerative colitis (Q24242289) ‎ (← links)
• Reduced Paneth cell alpha-defensins in ileal Crohn's disease (Q24538724) ‎ (← links)
• Side-stream smoking reduces intestinal inflammation and increases expression of tight junction proteins (Q24621817) ‎ (← links)
• Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis (Q24652503) ‎ (← links)
• Microbiota-based treatments in alcoholic liver disease (Q26740192) ‎ (← links)
• Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients (Q26750985) ‎ (← links)
• Fecal microbiota transplantation: in perspective (Q26765214) ‎ (← links)
• The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota (Q26773227) ‎ (← links)
• Role of antibiotics for treatment of inflammatory bowel disease (Q26774552) ‎ (← links)
• Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? (Q26777641) ‎ (← links)
• The Intestinal Microbiota in Inflammatory Bowel Disease (Q26795705) ‎ (← links)
• The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts (Q26823347) ‎ (← links)
• Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives (Q26864127) ‎ (← links)
• Individualized medicine and the microbiome in reproductive tract (Q26999090) ‎ (← links)
• Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease (Q27003192) ‎ (← links)
• Pathobionts of the gastrointestinal microbiota and inflammatory disease (Q27008113) ‎ (← links)
• Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease (Q27014906) ‎ (← links)
• Nutritional protective mechanisms against gut inflammation (Q27028202) ‎ (← links)
• Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip (Q27316911) ‎ (← links)
• Characterization of the core rumen microbiome in cattle during transition from forage to concentrate as well as during and after an acidotic challenge (Q27339851) ‎ (← links)
• Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases (Q28131810) ‎ (← links)
• Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms (Q28249095) ‎ (← links)
• Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats (Q28539513) ‎ (← links)
• The gut microbiota shapes intestinal immune responses during health and disease (Q29547727) ‎ (← links)
• Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach (Q29617547) ‎ (← links)
• Enteric pathogens through life stages (Q30425379) ‎ (← links)
• A2B adenosine receptor gene deletion attenuates murine colitis (Q30438772) ‎ (← links)
• Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease (Q30490594) ‎ (← links)
• A key role of dendritic cells in probiotic functionality (Q30830505) ‎ (← links)
• Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment (Q30945619) ‎ (← links)
• Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. (Q31160841) ‎ (← links)
• Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. (Q33270858) ‎ (← links)
• Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study (Q33296911) ‎ (← links)
• Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity (Q33309955) ‎ (← links)
• Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases (Q33341563) ‎ (← links)
• Differential effects of Bifidobacterium pseudolongum strain Patronus and metronidazole in the rat gut (Q33386647) ‎ (← links)
• Oral probiotic control skin inflammation by acting on both effector and regulatory T cells (Q33419855) ‎ (← links)
• Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases (Q33427772) ‎ (← links)
• Different fecal microbiotas and volatile organic compounds in treated and untreated children with celiac disease (Q33431774) ‎ (← links)
• Probiotics in the management of colonic disorders (Q33438518) ‎ (← links)
• Comparison of gut microbiota and allergic reactions in BALB/c mice fed different cultivars of rice (Q33505868) ‎ (← links)
• Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease (Q33521920) ‎ (← links)